Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer’s Disease

Ioanna Tsantzali; Aikaterini Foska; Eleni Sideri; Evdokia Routsi; Effrosyni Tsomaka; Dimitrios K. Kitsos; Christina Zompola; Anastasios Bonakis; Sotirios Giannopoulos; Konstantinos I. Voumvourakis; Georgios Tsivgoulis; George P. Paraskevas

doi:10.3390/biomedicines10081879

Biomedicines (Aug 2022)

Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer’s Disease

Ioanna Tsantzali,
Aikaterini Foska,
Eleni Sideri,
Evdokia Routsi,
Effrosyni Tsomaka,
Dimitrios K. Kitsos,
Christina Zompola,
Anastasios Bonakis,
Sotirios Giannopoulos,
Konstantinos I. Voumvourakis,
Georgios Tsivgoulis,
George P. Paraskevas

Affiliations

Ioanna Tsantzali: 2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” General University Hospital, 12462 Athens, Greece
Aikaterini Foska: 2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” General University Hospital, 12462 Athens, Greece
Eleni Sideri: 2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” General University Hospital, 12462 Athens, Greece
Evdokia Routsi: 2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” General University Hospital, 12462 Athens, Greece
Effrosyni Tsomaka: 2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” General University Hospital, 12462 Athens, Greece
Dimitrios K. Kitsos: 2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” General University Hospital, 12462 Athens, Greece
Christina Zompola: 2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” General University Hospital, 12462 Athens, Greece
Anastasios Bonakis: 2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” General University Hospital, 12462 Athens, Greece
Sotirios Giannopoulos: 2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” General University Hospital, 12462 Athens, Greece
Konstantinos I. Voumvourakis: 2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” General University Hospital, 12462 Athens, Greece
Georgios Tsivgoulis: 2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” General University Hospital, 12462 Athens, Greece
George P. Paraskevas: 2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” General University Hospital, 12462 Athens, Greece

DOI: https://doi.org/10.3390/biomedicines10081879
Journal volume & issue: Vol. 10, no. 8
p. 1879

Abstract

Read online

Cerebrospinal fluid (CSF) biomarkers remain the gold standard for fluid-biomarker-based diagnosis of Alzheimer’s disease (AD) during life. Plasma biomarkers avoid lumbar puncture and allow repeated sampling. Changes of plasma phospho-tau-181 in AD are of comparable magnitude and seem to parallel the changes in CSF, may occur in preclinical or predementia stages of the disease, and may differentiate AD from other causes of dementia with adequate accuracy. Plasma phospho-tau-181 may offer a useful alternative to CSF phospho-tau determination, but work still has to be done concerning the optimal method of determination with the highest combination of sensitivity and specificity and cost-effect parameters.

Published in Biomedicines

ISSN: 2227-9059 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Biology (General)
Website: http://www.mdpi.com/journal/biomedicines

About the journal

Abstract

Keywords